[Therapy of benign prostatic hyperplasia: terazosin or finasteride?].
Trinkler
F B
FB
Urologische Klinik, Universitätsspital, Zürich.
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D018120:Finasteride / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D011224:Prazosin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D014563:Urodynamics / Q000187:drug effects
D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors; D018120:Finasteride; C041226:Terazosin; D011224:Prazosin